Advertisements



Citi finds biotech executives jump ship ahead of bad drug trials

Analysis confirms what many on the Street were already thinking: biotech executives leaving ahead of late-stage clinical data often means the study will fail, according to one Citi’s Yigal... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkJul 2nd, 2019

Drug Legislation Likely to Dry Up Biotech Funding

Industry executives claim the proposed law will inhibit the development of life-saving medicationsRelated Stocks: ABBV, GILD, XNCR, MRK, LLY,.....»»

Category: blogSource: gurufocusNov 19th, 2019

Biogen resurrects Alzheimer"s drug; shares jump 35%

Biogen Inc revealed surprise plans to seek U.S. regulatory approval for its Alzheimer's treatment aducanumab on Tuesday, saying new analysis of clinical trials showed promise, just months after it had shelved two studies......»»

Category: topSource: moneycentralOct 22nd, 2019

The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict

Biotech stocks saw some strength last week. Positive clinical readouts, a couple of M&A deals and hopes of drug companies clinching a broader opioid settlement agreement worked in favor of the sector. read more.....»»

Category: blogSource: benzingaOct 20th, 2019

Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex"s Osteoporosis Biosimilar

Pfenex Inc (NYSE: PFNX) has a key binary event coming up: mark your calendar for Oct. 7, when the FDA is scheduled to issue its verdict on the company's lead drug candidate. read more.....»»

Category: blogSource: benzingaOct 3rd, 2019

Mallinckrodt’s plunges toward record low after report bankruptcy is being considered

Shares of Mallinckrodt PLC were rocked Thursday, putting them on track for a record low close, after a report that the specialty drug company had hired restructuring advisers and was considering bankruptcy ahead of federal opioid trials......»»

Category: topSource: marketwatchSep 5th, 2019

Mallinckrodt’s stock suffers record plunge after report bankruptcy is being considered

Shares of Mallinckrodt PLC were suffering their biggest-ever one-day selloff toward a record low Thursday, after a report that the specialty drug company had hired restructuring advisers and was considering bankruptcy ahead of federal opioid trials......»»

Category: topSource: marketwatchSep 5th, 2019

The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight

The biotech space saw muted activity in the week ended Aug. 30. Among the notable news of the week: Amgen, Inc. (NASDAQ: AMGN)'s $13.4-billion deal to buy the psoriasis drug Otezla from Celgene Corporation (NAS.....»»

Category: earningsSource: benzingaSep 2nd, 2019

What lies ahead after the Oklahoma opioid judgment?

Oklahoma's $572 million judgment against Johnson & Johnson will likely be followed by more trials and legal settlements seeking to hold a drug company accountable for a U.S. opioid crisis that has ripped apart lives and communities. .....»»

Category: topSource: moneycentralAug 27th, 2019

What lies ahead after the Oklahoma opioid judgment?

Oklahoma's $572 million judgment against Johnson & Johnson will likely be followed by more trials and legal settlements seeking to hold a drug company accountable for a U.S. opioid crisis that has ripped apart lives and communities. .....»»

Category: topSource: moneycentralAug 27th, 2019

The Week Ahead In Biotech: Pending Clinical Readouts In Focus

Biotech stocks headed south last week, reversing decent gains made in the previous week. Unfavorable FDA decisions, botched trials and weaker broader market sentiment all weighed down on the sector. read more.....»»

Category: blogSource: benzingaJun 29th, 2019

FDA OKs Expanded Indication For Ocular Therapeutix Eye Pain Drug Months Ahead Of Schedule

Micro-cap biotech Ocular Therapeutix Inc (NASDAQ: OCUL) announced Friday that it received FDA approval for an expanded indication for its eye pain drug. read more.....»»

Category: blogSource: benzingaJun 21st, 2019

The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Biotech stocks came under pressure this week ahead of the ASCO 2019 presentations. Headlines on legal woes related to the opioid crisis and drug price manipulation led to weakness in some stocks. read more.....»»

Category: blogSource: benzingaJun 1st, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Biotech stocks staged a recovery this week after being in the red in the previous two weeks. AbbVie Inc (NYSE: ABBV)'s psoriasis drug Skyrizi received FDA nod. The week also saw the release of strong quarterly earnings by big European pharma gian.....»»

Category: earningsSource: benzingaApr 27th, 2019

How free-flowing cash is accelerating small companies" cancer drug trials

An unprecedented biotech investment boom means smaller companies can accelerate early-stage drug trials and, potentially, carry them to more patients faster......»»

Category: topSource: bizjournalsApr 8th, 2019

5 biotech stocks that could be the next big winners

Pick your spots based on either high-potential drug trials or the likelihood of an acquisition......»»

Category: topSource: moneycentralMar 25th, 2019

Jeff Reeves"s Strength in Numbers: 5 biotech stocks that could be the next big winners

Pick your spots based on either high-potential drug trials or the likelihood of an acquisition......»»

Category: topSource: marketwatchMar 25th, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Biotech stocks came under pressure last week despite two FDA approvals coming through. read more.....»»

Category: blogSource: benzingaMar 23rd, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Biotech stocks came under pressure last week despite two FDA approvals coming through. The FDA approved SAGE Therapeutics Inc (NASDAQ:.....»»

Category: earningsSource: benzingaMar 23rd, 2019

Brainstorm Health: Biogen Alzheimer’s Drug, CVS Meets CBD, New CRISPR Company

Brainstorm Health Daily: March 21, 2019 Good afternoon, readers. It was a sad day for biopharma. Yet again, an Alzheimer’s drug hopeful crashed and burned in critical late-stage clinical trials. The victim, this time, was biotech gian.....»»

Category: europeSource: fortuneMar 21st, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

It was an event-filled one for biotech stocks, with the release of a slew of earnings, presentations of clinical trial results an.....»»

Category: earningsSource: benzingaMar 3rd, 2019